The effect of anti-glaucoma medications on the ocular surface.

This promotional topic was presented by Dr Ravin N Das on 21-08-05 at Hotel Satya Ashoka. The program was sponsored by Avesta Division of Sun Pharma.


Introduction

Increased chances of dry eye in glaucoma patients due to:


- Dry eye prevalence 6% at 40 years age to 15% at 65.
- Lower basal tear turnover in Glaucoma (Kuppens et al. AJO 1995)
- Topical therapies promote OSD

Topical therapies promote OSD


- Corneal and conjuctival epitheliopathy (Inou et al. Glaucoma 2005)
- Low grade conjunctival inflammation (Baudolin et al. Ophthalmology 1994; Noeker Cornea 2004)
- Epithelial apoptosis (Debbasch et al. IOVS 2001; Pisella et al. IOVS 2004)




Punctate epitheliopathy





Conjunctival inflammation - 1




Conjunctival inflammation - 2









Prior Glaucoma surgery Leading to an altered lid-globe relationship:-

- Bleb
- Shunt

Bleb - 1



Bleb - 2



Shunt



Ocular surface effects

- Irritation related symptoms
- Unstable tear film
- Blurred and fluctuating vision
- Altered corneal barrier
 - o stromal haze (colored haloes)
 - o infiltrates
 - o corneal ulceration

Management

- Eliminate offending agents toxic drops & preservatives.
 - Oral CAI (not always possible)
- Minimize preservative exposure.
 - ${\color{gray} \circ}\ {\color{gray} Non-preserved\ Timolol/Brimonidine} \\$
 - Lower BAK concentration (0.005 to 0.02%)
 - $\verb|OPURITE | Purite | Purite$
 - Switch to combinations reduce exposure to preservatives (applicable to patients on multi-drug therapy).
- Preserve tears
 - puntal occlusion may exacerbate corneal preservative toxicity.
- puntal occlusion may exacerb
 Decrease ocular surface inflammation
 - Steroids & NSAIDS
 - Tetracycline
 - Cyclosporine

- non-preservative
- good lubricant due to base
- doesn't raise IOP
- inhibits apoptosis of cornea and conjunctival epithelium.

Summary

Dry eye is prevalent in glaucoma patients.

Multifactorial:-

- reduced tear production
- altered tear distribution
- ocular surface disease from medication and preservative toxicity (due to epitheliopathy, conjunctivalinflammation and epithelial apoptosis)

Treatment requires:-

- Elimination of offending agents
- Improve or preserve tear turnover
- Decrease inflammation/apoptosis

Suggested remedy: Use preservative free (Purite® preserved) anti-glaucoma medications whenever possible...